BALANCE Model: Executive Summary and Strategic Architecture Analysis

ValuesEdge Institutional Intelligence | Classification: Strategic Briefing

---

1. Executive Summary and Strategic Context

What Is This Model and What Problem Does It Solve?

The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model is a voluntary CMMI demonstration authorized under Section 1115A of the Social Security Act that uses CMS's negotiating power as a centralized purchaser to unlock GLP-1 medication coverage for weight management in both Medicaid and Medicare Part D — two programs that currently exclude these drugs for that indication. The model launched for state Medicaid agencies beginning May 1, 2026, with Medicare Part D participation beginning January 1, 2027, and runs through December 31, 2031.

The core problem is structural: more than 70% of U.S. adults are classified as overweight or obese, creating downstream risk for type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and other metabolic conditions — yet the most clinically effective pharmacological interventions for weight management, GLP-1 receptor agonists, are largely inaccessible to Medicare and Medicaid beneficiaries due to statutory coverage exclusions and list-price economics that neither program could absorb at scale. BALANCE's mechanism is not a traditional payment reform that realigns provider incentives; it is a government-led drug price negotiation and coverage expansion model that pairs discounted drug access with mandatory manufacturer-provided lifestyle support — representing a structurally novel use of CMMI authority.

The six named model drugs currently included are all formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy® (Novo Nordisk and Eli Lilly products), the KwikPen formulation of Zepbound®, and Foundayo™. For Medicare Part D in CY 2027, Appendix C to the Part D Sponsor RFA specifies the complete NDC-level drug list, which also includes orforglipron tablets (pending FDA approval), with a negotiated GLP-1 Discounted Price of $245 per month supply across all participating model drugs — a single unified net price point that CMS negotiated directly with manufacturers during the pre-implementation period of January 12 through February 5, 2026.

Strategic Significance for the Value-Based Care Market

BALANCE is the first CMMI model in which CMS acts not as a payment system designer but as a direct price negotiator on behalf of downstream payers — Medicaid programs and Part D sponsors — using the purchasing leverage of combined Medicare and Medicaid beneficiary volume. This is philosophically and mechanically distinct from every prior CMMI drug-related model. It does not bundle drug costs into an episode, apply outcome-based warranties, or redirect savings through provider financial risk. Instead, it establishes a centralized GLP-1 price ceiling of $245/month, distributes that price to all participating payers simultaneously, and requires coverage terms standardized across state lines and plan types.

For ACO and integrated delivery system leaders, BALANCE matters indirectly but significantly: the model's coverage expansion will generate substantial new GLP-1 prescribing volume across Medicaid and Medicare populations who were previously unable to access these drugs. Providers and ACOs with large panels of qualifying beneficiaries — those with BMI ≥35, BMI ≥30 with comorbid hypertension or heart failure or CKD, or BMI ≥27 with pre-diabetes or prior MI or stroke — should anticipate increased prescribing demand, prior authorization workflow changes, and potential downstream reductions in downstream utilization of diabetes and cardiovascular services as metabolic health improves.

For Medicare Advantage plan strategists and Part D sponsors, BALANCE presents a direct financial and competitive design decision. The model requires participating organizations to cover model drugs at or below $50/month copay for Enhanced Alternative and EGWP plans and at or below $125/month for Basic Alternative and Actuarially Equivalent plans in the initial coverage phase — cost-sharing levels far below current market practice for GLP-1s. The model also includes optional risk corridor modifications and potential future payment adjustment factors that make participation financially attractive for plans with higher-risk populations who will benefit most from GLP-1 therapy.

For state Medicaid agency and managed care organization leaders, BALANCE is an operational and political inflection point. States that join the model gain access to confidential GLP-1 Discounted Pricing negotiated by CMS (distributed via secure Box folder per the State RFA), must adopt standardized coverage criteria across both FFS and managed care delivery systems by January 1, 2027, and must ensure managed care plan policies align with model Key Terms — a meaningful managed care contract alignment requirement that will require coordination between Medicaid agencies and their MCO partners well before go-live.

Political Context and Administrative Alignment

BALANCE was announced December 23, 2025 — two days before Christmas, two days into the second week of the transition period for the incoming Trump administration — and the Manufacturer RFA carried a submission deadline of January 8, 2026, with pre-implementation negotiations running from January 12 through February 5, 2026. This timeline placed the substantive drug price negotiations squarely in the early weeks of the Trump administration under HHS Secretary Robert F. Kennedy Jr., CMS Administrator Dr. Mehmet Oz, and CMMI Director Abe Sutton.

The model's policy content aligns well with several priorities of the current administration: reducing prescription drug prices through direct negotiation rather than through the IRA's Drug Price Negotiation Program (the model explicitly contemplates waivers from Maximum Fair Price requirements for model drugs), expanding access to weight management treatment without mandating broad coverage through rulemaking, and using a demonstration model framework that is inherently voluntary and avoids statutory change. RFK Jr.'s documented interest in nutrition and metabolic health as prevention strategy provides an additional policy tailwind. The model's emphasis on lifestyle intervention as a condition of drug access also resonates with the administration's broader "Make America Healthy Again" framing.

The Medicare GLP-1 Bridge — extended through December 31, 2027 — fills the gap between model Medicaid launch and full Part D implementation, giving CMS a data collection vehicle on GLP-1 utilization patterns in Medicare while the Part D model ramps up. The explicit statement that the "BALANCE Model not launching in Medicare in 2027" has already been publicly acknowledged as a contingency, with the Bridge extension serving as the fallback, suggests CMS is managing political and operational risk with a layered launch strategy.

Market Transformation Implications

The model's 80% participation threshold for Medicare Part D is the most consequential structural feature for market dynamics. If at least 80% of NAMBA-eligible Part D beneficiary enrollment opts in — calculated on February 2026 enrollment data with CY 2027 projections — the model proceeds for Medicare. If not, it does not. This threshold was explicitly designed to prevent adverse selection, ensuring that high-risk beneficiaries cannot selectively cluster in participating plans. The April 30, 2026 target notification date means Part D sponsors had roughly six weeks from the application deadline to learn whether the model would proceed — a tight window with significant bid implications.

At scale, universal or near-universal Part D plan participation would establish $245/month as the effective Medicare GLP-1 market price for weight management indications — a potentially landmark benchmark that could influence commercial pricing negotiations, state Medicaid supplemental rebate discussions outside the model, and future statutory drug pricing debates.

---

2. Model Architecture and Payment Structure

Participation Structure and Eligibility

BALANCE involves three distinct participant categories — manufacturers, state Medicaid agencies, and Part D plan sponsors — each with separate RFAs, eligibility standards, and legal agreements.

Manufacturer Eligibility requires that eligible products: (a) contain an active ingredient FDA-approved for weight management (or expected to receive such approval by January 1, 2027); (b) act as a GIP receptor agonist, GLP-1 receptor agonist, glucagon receptor agonist, or combination thereof; and (c) demonstrate at least 9.5% average body weight reduction at an FDA-approved dose per a randomized clinical trial primary or secondary endpoint. Manufacturers that submitted applications by January 8, 2026, participated in CMS negotiations during the January 12 – February 5, 2026 pre-implementation period and were required to execute a Participation Agreement (PA) with CMS by February 28, 2026 to become model participants.

State Medicaid Eligibility is open to all states, the District of Columbia, and U.S. territories participating in the Medicaid Drug Rebate Program (MDRP). State applications were due via Qualtrics by 11:59 PM EDT on July 31, 2026. State Agreements must be executed by January 1, 2027. In 2026 and 2027, participating states must adopt the Medicaid Key Terms for all model drugs from all participating manufacturers — no selective adoption of individual manufacturer agreements is permitted. States may begin with FFS-only populations and add managed care populations later, so long as all Medicaid populations are included by January 1, 2027.

Part D Plan Sponsor Eligibility encompasses PDPs and MA-PD plans (HMO, HMOPOS, Local and Regional PPO), Special Needs Plans (excluding Defined Standard D-SNPs), and EGWPs. Excluded plan types include private fee-for-service plans, PACE organizations, LI-NET, fallback plans, and religious fraternal benefit plans. Defined Standard plans cannot participate unless converted to Basic Alternative or Actuarially Equivalent status. Participation is determined at the parent organization level, with organizations required to include all Enhanced Alternative plans and 90% of beneficiary enrollment in basic plans.

Model Timeline

Milestone	Date
Model Announcement	December 23, 2025
Manufacturer RFA Released	December 19, 2025
Manufacturer Application Deadline	January 8, 2026, 11:59 PM EDT
Pre-Implementation Negotiation Period	January 12 – February 5, 2026
Manufacturer PA Execution Deadline	February 28, 2026
State Medicaid RFA Released	March 9, 2026
Part D Sponsor RFA Released	March 9, 2026
Part D Application Deadline	April 20, 2026, 11:59 PM PDT
Part D Threshold Notification Target	April 30, 2026
Conditional Part D Approvals Sent	May 18, 2026
Medicaid Model Launch Window Opens	May 1, 2026
Medicare GLP-1 Bridge Begins	July 1, 2026
State Application Deadline	July 31, 2026, 11:59 PM EDT
Part D Bid Deadline (CY 2027)	June 1, 2026
State Agreement Execution Deadline	January 1, 2027
CY 2027 Part D Contract Addendum Executed	September 2026
Medicare Part D BALANCE Model Launch	January 1, 2027
Medicare GLP-1 Bridge End	December 31, 2027
Model End	December 31, 2031

Payment Methodology: Medicare Part D

The GLP-1 Discounted Price of $245 per month supply established for CY 2027 applies uniformly across all model drugs and all participating Part D plans. This price represents the net price after accounting for all applicable discounts, rebates, and other price concessions, including Manufacturer Discount Program (MDP) amounts.

Payment effectuation uses a novel "Facilitated DIR" (FAD) PDE field — a new data field through which CMS will calculate the manufacturer rebate owed on each claim by computing the difference between the ingredient cost reported by the plan sponsor on the PDE and the sum of the GLP-1 Discounted Price plus the MDP amount. Manufacturers will be invoiced quarterly via the existing Manufacturer Payment Portal, using separate model-specific invoices. Gross drug costs for calculation purposes are based on wholesale acquisition cost (WAC), not Maximum Fair Price, for drugs selected under the IRA Drug Price Negotiation Program.

A 340B adjustment of up to 5% downward applies to model rebates to account for units dispensed through 340B covered entities at discounted acquisition costs.

For model drugs subject to Maximum Fair Prices under the IRA Negotiation Program, CMMI is pursuing a waiver of Section 1860D-2(d)(1)(D) to allow manufacturers to provide model-associated rebates in lieu of MFP effectuation — a significant structural carve-out that prevents double-counting and allows the BALANCE price to govern regardless of IRA negotiated pricing.

Pharmacy reimbursement must be at no less than WAC plus sales tax plus a dispensing fee at in-network pharmacies. Out-of-network pharmacies are subject to standard OON cost-sharing rules rather than model price caps.

Beneficiary Cost-Sharing Structure: Medicare Part D

Plan Type	Deductible Phase Maximum	Initial Coverage Phase Maximum	Catastrophic Phase
Enhanced Alternative (EA) and EGWPs	$245 + dispensing fee per 28- or 30-day fill	$50 per 28- or 30-day supply	$0
Basic Alternative (BA) and Actuarially Equivalent (AE)	$245 + dispensing fee per 28- or 30-day fill	$125 per 28- or 30-day supply	$0
D-SNPs (territories only)	Subject to reduced cost-sharing per Table 1	Subject to reduced cost-sharing per Table 1	$0
D-SNPs (non-territory)	Not subject to model cost-sharing maximums	Not subject to model cost-sharing maximums	Standard

Cost sharing maximums must be applied uniformly across all model drugs and all in-network pharmacy types (preferred, non-preferred, retail, mail). Plans may set cost sharing below the stated maximums but must apply the lower amount uniformly across all model drugs.

Coverage Criteria: Prior Authorization Standards

The standardized prior authorization (PA) criteria are identical for both Medicaid and Medicare Part D and require provider attestation that the patient: (a) has type 2 diabetes; (b) has noncirrhotic MASH with F2–F3 liver fibrosis; (c) has obstructive sleep apnea; or (d) is currently on and will continue lifestyle modification and meets one of three BMI-based thresholds:

BMI Threshold	Required Comorbid Condition(s)
BMI ≥35 (age ≥18)	None required beyond BMI
BMI ≥30 (age ≥18)	Heart failure with preserved EF; uncontrolled hypertension (SBP >140 or DBP >90 on ≥2 antihypertensives); CKD stage 3a+; moderate/severe OSA (AHI >15); noncirrhotic MASH F2/F3
BMI ≥27 (age ≥18)	Pre-diabetes (ADA definition); prior MI; prior stroke; symptomatic peripheral artery disease

Step therapy may not include lifestyle or similar requirements. PA criteria may not be more burdensome than the standardized criteria listed above. For Part D, plans must attempt automated ICD-10 lookback (Auto-Lookback) before requiring manual provider attestation.

States may adopt less restrictive criteria within FDA-approved label bounds. CMS will not approve variations that disadvantage one model drug relative to another unless the difference corresponds to FDA label differences.

Medicaid Payment Structure

Medicaid price reductions occur via Supplemental Rebate Agreements (SRAs) between participating states and manufacturers, layered on top of existing MDRP statutory rebates. The specific GLP-1 Discounted Pricing negotiated by CMS is distributed to states through a confidential Box folder (Appendix B of the State RFA) and applies on an NDC-level basis. States access supplemental rebates according to the GLP-1 Discounted Price beginning on their Model SRA start date.

Rebates are calculated on a Gross Net Unit Price (GNUP) basis, with specific per-unit supplemental rebate amounts determined through manufacturer negotiations. States that have existing SRAs with participating manufacturers must either terminate those SRAs or amend them to comply with model SRA requirements before the model SRA takes effect.

Key Terms — including GLP-1 Discounted Pricing, clinical criteria, the model drug list, and lifestyle support parameters — are effective through December 31, 2027, after which CMS and manufacturers may renegotiate on an annual basis.

Risk Corridor Incentive for Part D Plans

Part D sponsors opting into the narrowed first risk corridor must elect this option at the time of application. Eligibility is triggered if a plan's model drug utilization rate exceeds one standard deviation above the mean for its plan type among all eligible participating plans that opted into the narrowed corridor.

Cost Variance	Standard Part D Plan Responsibility	Standard CMS Responsibility
±0–5%	100%	0%
±5–10%	50%	50%
±10% and beyond	20%	80%

Cost Variance	BALANCE Narrowed Corridor Plan Responsibility	BALANCE Narrowed Corridor CMS Responsibility
±0–2.5%	100%	0%
±2.5–10%	50%	50%
±10% and beyond	20%	80%

The narrowed corridor compresses the plan's full-risk band from ±5% to ±2.5%, increasing CMS's shared-risk exposure beginning at a lower deviation threshold. EGWPs are explicitly excluded from this incentive. CMS will calculate eligibility in the months following the completed plan year, with results targeted for release to participating plans in July following the plan year. This incentive is available on an opt-in basis for the first two years of the model, with CMMI reserving the right to extend it based on results.

Lifestyle Support Program Requirements

All manufacturers participating in the model are required to provide a lifestyle support program at no cost to beneficiaries receiving model drugs under BALANCE — both in Medicaid and Medicare. This is a mandatory condition of the Manufacturer PA and is covered under the CMS-sponsored model safe harbor at 42 CFR §1001.952(ii), eliminating the need for a separate fraud and abuse waiver.

The program must meet defined component requirements across five dimensions: Diet & Nutrition (healthy eating, GI side-effect reduction, nutritional deficiency prevention, muscle/bone health); Physical Activity (access to services and counseling with goal setting); Medication Adherence (reminders, side-effect guidance, injection site rotation for injectables); Recurrence (regular beneficiary engagement, weight logging, asynchronous education, demonstrated timely engagement); and Scale & Accessibility (available offline via telephone or in-person for beneficiaries with limited digital access, compliant with HHS IT standards for any digital components).

CMS explicitly reserves the right to shift lifestyle support responsibility from manufacturers to states and MA-PD plans in future years based on model performance — a provision that health plan strategists should flag as a potential future contractual obligation requiring clinical infrastructure investment.

Quality Monitoring and Evaluation

CMS will monitor beneficiary access to model drugs, access to related care, health outcomes, beneficiary experience, and affordability and adherence impacts using T-MSIS for Medicaid and Part D Prescription Drug Event (PDE) data for Medicare, supplemented by patient-reported data on lifestyle support program impact. An independent contractor will conduct the formal model evaluation. CMS reserves the right to terminate a participating state's SA or a manufacturer's PA for poor performance, program integrity violations, or non-compliance, and may investigate any participant upon evidence of adverse quality-of-care impacts.